Category: Parkinson's Disease: Cognitive functions
Objective: To increase the reliability of the development of dementia in patients with PD by a comparative assessment of clinical scales and neurosteroids
Background: Parkinson’s disease (PD) is one of the most common neurological diseases, which is very common in the elderly. According to population studies, dementia occurs in 20-40% of patients with PD and becomes the main cause of maladaptation of patients.
Method: We examined 80 patients with PD, who were divided into 30 patients depending on the presence or absence of cognitive impairment and dementia. As a control, we also examined on a voluntary basis 20 healthy persons recognized as such by a special commission
The diagnostic efficacy of neurosteroids has been established, including the level of DHEAS and cortisol in the blood serum of patients for early diagnosis of cognitive impairment and monitoring the effectiveness of therapy, identifying a risk group in PD. Cognitive status was analyzed using the MMSEs cale ,FAB and MoCa to identify dementia.
Results: Test indicators of cognitive impairment revealed a distinct difference in digital values, characterized by low data on MMSE, FAB and MoCa in patients of the main group.
Cortisol revealed a tendency to its increase in the blood in patients of the main group (1053,9±39,1), both in relation to the comparative(616±16,5) and control groups (437,4±13,3). The level of dehydroepiandresterone sulfate progressively decreased, reaching its minimum value in patients of the main group (2,4±0,4). The comparative group (6,3±0,7) in this case occupied a borderline value.
Two bipolar tendencies between hormones were identified in the form of a direct relationship with cortisol and an inverse relationship with dehydroepiandresterone sulfate. However, the significance of these relationships with the scales was at different levels of significance. So, in the case of cortisol, the inverse correlation gradually increased depending on the level of approximation of the MMSE/FAB/MoCa scales. At the same time, the level of the hormone dehydroepiandrosterone sulfate did not change unequivocally.
Conclusion: The diagnostic efficacy of neurosteroids was established, including the level of dehydroepiandrosterone sulfate and cortisol in the blood serum of patients for the early diagnosis of cognitive impairment and monitoring the effectiveness of therapy, identifying a risk group in PD.
References: 1.Rakhimbaeva G.S., Akramova D.T/ Role Of Increasing Levels Of The Hormone Cortisol In Cognitive Impairment In Parkinson’s Disease:Vascular Parkinsonism //European Journal of Molecular & Clinical Medicine/ /ISSN 2515-8260/ Volume 07, Issue 06, 2020 2987.
2.Рахимбаева Г.С, Акрамова Д.Т. Паркинсон кассалиги, васкуляр паркинсонизм ва Алцгеймер касалликларда кортизол гормони микдорини ўзгариши ва бу ўзгаришларнинг когнитив бузилишлар ривожлаништдаги роли // «Nevrologiya»—1(81), 2020
3.Толибов Д.С., Рахимбаева Г.С. Апробация нового диагностического комплекса биомаркеров для дифференциальной диагностики болезни Альгеймера // Журнал Медициеские новости, 2018, №6, с.65-69
To cite this abstract in AMA style:
DI. Okhunova, G. Sattarovna, A. Babokhujaev. Predicting the development of dementia in patients with Parkinson’s disease by comparing neurosteroids in the blood level [abstract]. Mov Disord. 2022; 37 (suppl 2). https://www.mdsabstracts.org/abstract/predicting-the-development-of-dementia-in-patients-with-parkinsons-disease-by-comparing-neurosteroids-in-the-blood-level/. Accessed June 15, 2025.« Back to 2022 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/predicting-the-development-of-dementia-in-patients-with-parkinsons-disease-by-comparing-neurosteroids-in-the-blood-level/